What is the approximate market price of Deflazacort?

Deflazacort is a glucocorticoid drug mainly used for the long-term management of patients with Duchenne muscular dystrophy. Through its anti-inflammatory and immunomodulatory effects, it delays muscle damage, improves muscle strength and, to some extent, slows the progression of disability. Although the original drug has not yet been officially launched in China, it has been used in overseas markets, providing patients with reliable treatment options. The specifications of the European version of the original drug are 6mg*100 tablets per box, and the price is about more than 1,000 yuan, while overseas generic drugs of the same specifications, such as those produced in India, sell for about 300 yuan. The price may fluctuate due to exchange rates and regional differences.

In practical applications, patients need to strictly follow medical instructions and use medications rationally according to weight and age. During long-term treatment, blood pressure, blood sugar, bone density, liver and kidney function, and growth and development indicators should be monitored regularly to prevent potential side effects from affecting the patient's health. Families and medical care teams should maintain communication to ensure treatment compliance, and at the same time combine rehabilitation training and nutritional intervention to comprehensively improve treatment effects.

Although the original drug of deflazacort is not yet on the market in China, the availability of overseas drugs allows patients and family members to obtain treatment drugs through formal channels and use them under the guidance of professional doctors. Long-term standardized medication can not only improve muscle strength, but also delay the progression of disability and provide patients with a higher quality of daily life. With the future domestic launch of original drugs and policy support, patients are expected to obtain more convenient ways to purchase drugs and reasonable economic compensation, thereby better achieving standardized treatment goals.

Taken together, deflazacort plays an irreplaceable role in the treatment of Duchenne muscular dystrophy. Its scientific application and long-term management strategy can provide patients with continuous, effective and safe treatment guarantees, and provide an important reference for clinical practice and public health management.

Reference: https://www.drugs.com/mtm/deflazacort.html